Skip to main content
SpringerLink
Log in

Synthetische Cannabinoide

Forensische Relevanz und Interpretation analytischer Befunde

Synthetic cannabinoids

Forensic relevance and interpretation of analytical findings

  • CME Zertifizierte Fortbildung
  • Published:
Rechtsmedizin Aims and scope Submit manuscript

Zusammenfassung

In den vergangenen Jahren erreichte weltweit eine wahre Flut von neuen, auch als „legal highs“ bezeichneten Drogenprodukten den Markt. Während in einigen Teilen der Welt eher die amphetaminartigen Stimulanzien dominieren, stellen in Deutschland bisher die synthetischen Cannabinoide das größere Problem dar. Die hohe Dynamik, die durch rasche Aufnahme neuer Substanzen in die Anlagen des Betäubungsmittelgesetzes und den Ersatz auf Herstellerseite durch chemisch-strukturell leicht veränderte, neue Substanzen zustande kommt, stellt sowohl die Kriminaltechnik als auch die Toxikologie vor immense Herausforderungen.

Abstract

In recent years a flood of new psychoactive substances offered as “legal highs” appeared on the drugs market worldwide. In some parts of the world amphetamine-type stimulants are predominant but in Germany synthetic cannabinoids represent the bigger problem. The high dynamics which are maintained by the “cat and mouse game” of scheduling substances and the producers circumventing the regulations by adding new, chemically modified substances, poses a great challenge for both forensic science and toxicology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 1
Abb. 2

Literatur

  1. Mechoulam R, Gaoni Y (1965) A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275

    Article  PubMed  CAS  Google Scholar 

  2. Matsuda LA, Lolait SJ, Brownstein MJ et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564

    Article  PubMed  CAS  Google Scholar 

  3. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65

    Article  PubMed  CAS  Google Scholar 

  4. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179–202

    Article  PubMed  CAS  Google Scholar 

  5. Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45–60

    Article  PubMed  CAS  Google Scholar 

  6. Thakur GA, Tichkule R, Bajaj S, Makriyannis A (2009) Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 19:1647–1673

    Article  PubMed  CAS  Google Scholar 

  7. Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713

    Article  PubMed  CAS  Google Scholar 

  8. Auwärter V, Dresen S, Weinmann W et al (2009) „Spice“ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837

    Article  PubMed  Google Scholar 

  9. Werse B, Morgenstern C (2011) Abschlussbericht – Online-Befragung zum Thema „Legal Highs“. Centre for Drug Research, Goethe-Universität, Frankfurt a. M.

  10. Pabst A, Piontek D, Kraus L, Müller S (2010) Substanzkonsum und substanzbezogene Störungen. Ergebnisse des Epidemiologischen Suchtsurveys 2009. Sucht 56:327–336

    Google Scholar 

  11. Werse B, Müller O, Schell C, Morgenstern C (2011) Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2010. Centre for Drug Research, Goethe-Universität, Frankfurt a. M.

  12. Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35:1803–1810

    Article  PubMed  CAS  Google Scholar 

  13. Howlett AC, Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532–538

    PubMed  CAS  Google Scholar 

  14. Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231–232

    Article  PubMed  CAS  Google Scholar 

  15. Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89:3825–3829

    Article  PubMed  CAS  Google Scholar 

  16. Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949

    Article  PubMed  CAS  Google Scholar 

  17. Johnson DE, Heald SL, Dally RD et al (1993) Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids 48:429–437

    Article  PubMed  CAS  Google Scholar 

  18. Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90

    Article  PubMed  CAS  Google Scholar 

  19. Mascia MS, Obinu MC, Ledent C et al (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 383:R1–2

    Article  PubMed  CAS  Google Scholar 

  20. Fernandez-Ruiz J, Berrendero F, Hernandez ML et al (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23:14–20

    Article  PubMed  CAS  Google Scholar 

  21. Johnson MR, Rice KC, Howlett A et al (1992) The cannabinoid receptor – pharmacologic identification, anatomical localization and cloning. NIDA Res Monogr 119:86–90

    PubMed  CAS  Google Scholar 

  22. Pavlopoulos S, Thakur GA, Nikas SP et al (2006) Cannabinoid receptors as therapeutic targets. Curr Pharm Des 12:1751–1769

    Article  PubMed  CAS  Google Scholar 

  23. Ishac EJ, Jiang L, Lake KD et al (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028

    Article  PubMed  CAS  Google Scholar 

  24. Kathmann M, Bauer U, Schlicker E et al (1999) Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 359:466–470

    Article  PubMed  CAS  Google Scholar 

  25. Nakazi M, Bauer U, Nickel T et al (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 361:19–24

    Article  PubMed  CAS  Google Scholar 

  26. Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322–4334

    PubMed  CAS  Google Scholar 

  27. Szabo B, Müller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73:1084–1089

    Article  PubMed  CAS  Google Scholar 

  28. Felder CC, Joyce KE, Briley EM et al (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450

    PubMed  CAS  Google Scholar 

  29. Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6:757–773

    PubMed  CAS  Google Scholar 

  30. Wiley JL, Martin BR (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57–63

    Article  PubMed  CAS  Google Scholar 

  31. Forrester MB, Kleinschmidt K, Schwarz E, Young A (2011) Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 30:351–358

    Article  PubMed  Google Scholar 

  32. Hoyte CO, Jacob J, Monte AA et al (2012) A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med, DOI 10.1016/j.annemergmed.2012.03.007

  33. Pant S, Deshmukh A, Dholaria B et al (2012) Spicy seizure. Am J Med Sci 344:67–68

    Article  PubMed  Google Scholar 

  34. Schneir AB, Baumbacher T (2012) Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 8:62–64

    Article  PubMed  Google Scholar 

  35. Aung MM, Griffin G, Huffman JW et al (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 60:133–140

    Article  PubMed  CAS  Google Scholar 

  36. Compton DR, Rice KC, De Costa BR et al (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218–226

    PubMed  CAS  Google Scholar 

  37. D’Ambra TE, Estep KG, Bell MR et al (1992) Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124–135

    Article  Google Scholar 

  38. Deng H, Gifford AN, Zvonok AM et al (2005) Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 48:6386–6392

    Article  PubMed  CAS  Google Scholar 

  39. Frost JM, Dart MJ, Tietje KR et al (2010) Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 53:295–315

    Article  PubMed  CAS  Google Scholar 

  40. Huffman JW, Mabon R, Wu MJ et al (2003) 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 11:539–549

    Article  PubMed  CAS  Google Scholar 

  41. Huffman JW, Padgett LW (2005) Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 12:1395–1411

    Article  PubMed  CAS  Google Scholar 

  42. Huffman JW, Padgett LW, Isherwood ML et al (2006) 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett 16:5432–5435

    Article  PubMed  CAS  Google Scholar 

  43. Huffman JW, Szklennik PV, Almond A et al (2005) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110–4113

    Article  PubMed  CAS  Google Scholar 

  44. Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives, W.I.P. Organization (Patent)

  45. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999

    PubMed  CAS  Google Scholar 

  46. Mir A, Obafemi A, Young A, Kane C(2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:e1622–e1627

    Article  PubMed  Google Scholar 

  47. Schmid K, Niederhoffer N, Szabo B (2003) Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch Pharmacol 368:301–308

    Article  PubMed  CAS  Google Scholar 

  48. Advisory Council on the Misuse of Drugs (ACMD) (2009) Consideration of the major cannabinoid agonists. Home Office, London

  49. Howlett AC, Barth F, Bonner TI et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202

    Article  PubMed  CAS  Google Scholar 

  50. Thakur GA, Nikas SP, Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631–640

    Article  PubMed  CAS  Google Scholar 

  51. Huffman J (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. In: Reggio PH (Hrsg) The cannabinoid receptors. Humana, New York

  52. Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of „Spice“ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585–593

    Article  PubMed  CAS  Google Scholar 

  53. Teske J, Weller JP Fieguth A et al (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2659–2663

    Article  PubMed  CAS  Google Scholar 

  54. Dresen S, Kneisel S, Weinmann W et al (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 46:163–171

    Article  PubMed  CAS  Google Scholar 

  55. Kacinko SL, Xu A, Homan JW et al (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 35:386–393

    Article  PubMed  CAS  Google Scholar 

  56. Ammann J, Mc Laren JM, Gerostamoulos D, Beyer J et al (2012) Detection and quantification of new designer drugs in human blood: part 1 – synthetic cannabinoids. J Anal Toxicol 36:372–380

    Article  PubMed  CAS  Google Scholar 

  57. Poklis JL, Amira D, Wise LE et al (2012) Detection and disposition of JWH-018 and JWH-073 in mice after exposure to „Magic Gold“ smoke. Forensic Sci Int. DOI 10.1016/j.forsciint.2012.02.003

  58. Shanks KG, Dahn T, Terrell AR (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 36:145–152

    Article  PubMed  CAS  Google Scholar 

  59. Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom. DOI 10.1002/jms.3020

  60. Coulter C, Garnier M, Moore C (2011) Synthetic cannabinoids in oral fluid. J Anal Toxicol 35:424–430

    Article  PubMed  CAS  Google Scholar 

  61. Salomone A, Gerace E, D’Urso F et al (2012) Simultaneous analysis of several synthetic cannabinoids, THC, CBD and CBN, in hair by ultra-high performance liquid chromatography tandem mass spectrometry. Method validation and application to real samples. J Mass Spectrom 47:604–610

    Article  PubMed  CAS  Google Scholar 

  62. Hutter M, Kneisel S, Auwärter V, Neukamm MA (2012) Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (in press)

  63. Möller I, Wintermeyer A, Bender K et al (2011) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3:609–620

    Article  PubMed  Google Scholar 

  64. Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‚herbal mixtures‘ using LC-MS/MS techniques. J Mass Spectrom 47:54–65

    Article  PubMed  CAS  Google Scholar 

  65. Moran CL, Le VH, Chimalakonda KC et al (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228–4236

    Article  PubMed  CAS  Google Scholar 

  66. Johansson E, Halldin MM (1989) Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218–223

    PubMed  CAS  Google Scholar 

  67. Fraser AD, Worth D (2003) Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int 133:26–31

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Institut für Rechtsmedizin, Universitätsklinikum Freiburg, Albertstr. 9, 79104, Freiburg, Deutschland

    V. Auwärter, S. Kneisel, M. Hutter & A. Thierauf

Authors
  1. V. Auwärter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kneisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Hutter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Thierauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Auwärter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Auwärter, V., Kneisel, S., Hutter, M. et al. Synthetische Cannabinoide. Rechtsmedizin 22, 259–271 (2012). https://doi.org/10.1007/s00194-012-0810-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00194-012-0810-4

Schlüsselwörter

Keywords

Search

Navigation